1. bookVolumen 71 (2021): Edición 2 (June 2021)
Detalles de la revista
License
Formato
Revista
eISSN
1846-9558
Primera edición
28 Feb 2007
Calendario de la edición
4 veces al año
Idiomas
Inglés
Acceso abierto

Efficacy and safety of the metformin-mazindol anorectic combination in rat

Publicado en línea: 04 Nov 2020
Volumen & Edición: Volumen 71 (2021) - Edición 2 (June 2021)
Páginas: 279 - 291
Aceptado: 20 Jun 2020
Detalles de la revista
License
Formato
Revista
eISSN
1846-9558
Primera edición
28 Feb 2007
Calendario de la edición
4 veces al año
Idiomas
Inglés

1. W. T. Cefalu, G. A. Bray, P. D. Home, W. T. Garvey, S. Klein, F. X. Pi-Sunyer, F. B. Hu, I. Raz, L. Van Gaal, B. M. Wolfe and D. H. Ryan, Advances in the science, treatment, and prevention of the disease of obesity: Reflections from a diabetes care editors’ expert forum, Diabetes Care38 (2015) 1567–1582; https://doi.org/10.2337/dc15-108110.2337/dc15-1081Search in Google Scholar

2. Global BMI Mortality Collaboration, E. Di Angelantonio, S. Bhupathiraju, D. Wormser, P. Gao, S. Kaptoge, A. Berrington de Gonzalez, B. J. Cairns, R. Huxley, Ch. L. Jackson, G. Joshy, S. Lewington, J. E. Manson, N. Murphy, A. V. Patel, J. M. Samet, M. Woodward, W. Zheng, M. Zhou, N. Bansal, A. Barricarte, B. Carter, J. R. Cerhan, G. D. Smith, X. Fang, O. H. Franco, J. Green, J. Halsey, J. S. Hildebrand, K. J. Jung, R. J. Korda, D. F. McLerran, S. C. Moore, L. M. O’Keeffe, E. Paige, A. Ramond, G. K. Reeves, B. Rolland, C. Sacerdote, N. Sattar, E. Sofianopoulou, J. Stevens, M. Thun, H. Ueshima, L. Yang, Y. D. Yun, P. Willeit, E. Banks, V. Beral, Zh. Chen, S. M. Gapstur, M. J. Gunter, P. Hartge, S. H. Jee, T. H. Lam, R. Peto, J. D. Potter, W. C. Willett, S. G. Thompson, J. Danesh and F. B. Hu, Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents, Lancet388 (2016) 776–786; https://doi.org/10.1016/S0140-6736(16)30175-110.1016/S0140-6736(16)30175-1Search in Google Scholar

3. F. L. Greenway, Physiological adaptations to weight loss and factors favouring weight regain, Int. J. Obes. (London) 39 (2015) 1188–1196; https://doi.org/10.1038/ijo.2015.5910.1038/ijo.2015.59476692525896063Search in Google Scholar

4. C. Langenberg, S. J. Sharp, P. W. Franks, R. A. Scott, P. Deloukas, N. G. Forouhi, P. Froguel, L. C. Groop, T. Hansen, L. Palla, O. Pedersen, M. B. Schulze, M. J. Tormo, E. Wheeler, C. Agnoli, L. Arriola, A. Barricarte, H. Boeing, G. M. Clarke, F. Clavel-Chapelon, E. J. Duell, G. Fagherazzi, R. Kaaks, N. D. Kerrison, T. J. Key, K. T. Khaw, J. Kröger, M. Lajous, A. P. Morris, C. Navarro, P. M. Nilsson, K. Overvad, D. Palli, S. Panico, J. R. Quirós, O. Rolandsson, C. Sacerdote, M. J. Sánchez, N. Slimani, A. M. Spijkerman, R. Tumino, D. L. van der A, Y. T. van der Schouw, I. Barroso, M. I. McCarthy, E. Riboli and N. J. Wareham, Gene-lifestyle interaction and type 2 diabetes: the EPIC interact case-cohort study, PLoS Med.11 (2014) e1001647; https://doi.org/10.1371/journal.pmed.100164710.1371/journal.pmed.1001647402818324845081Search in Google Scholar

5. J. Jordan, A. Astrup, S. Engeli, K. Narkiewicz, W. W. Day and N. Finer, Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity, J. Hypertens.32 (2014) 1178–1188; https://doi.org/10.1097/HJH.000000000000014510.1097/HJH.0000000000000145401156724621808Search in Google Scholar

6. S. K. Malin and S. R. Kashyap, Effects of metformin on weight loss: potential mechanisms, Curr. Opin. Endocrinol. Diabetes Obes.21 (2014) 323–329; https://doi.org/10.1097/MED.000000000000009510.1097/MED.000000000000009525105996Search in Google Scholar

7. G. Aubert, V. Mansuy, M. J. Voirol, L. Pellerin and F. P. Pralong, The anorexigenic effects of metformin involve increases in hypothalamic leptin receptor expression, Metabolism60 (2011) 327–334; https://doi.org/10.1016/j.metabol.2010.02.00710.1016/j.metabol.2010.02.00720303124Search in Google Scholar

8. J. R. Lindsay, N. A. Duffy, A. M. McKillop, J. Ardill, F. P. O’Harte, P. R. Flatt and P. M. Bell, Inhibition of dipeptidyl peptidase IV activity by oral metformin in type 2 diabetes, Diabet. Med.22 (2005) 654–657; https://doi.org/10.1111/j.1464-5491.2005.01461.x10.1111/j.1464-5491.2005.01461.x15842525Search in Google Scholar

9. A. J. Mulherin, A. H. Oh, H. Kim, A. Grieco, L. M. Lauffer and P. L. Brubaker, Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell, Endocrinology152 (2011) 4610–4619; https://doi.org/10.1210/en.2011-148510.1210/en.2011-148521971158Search in Google Scholar

10. W. C. Knowler, E. Barrett-Connor, S. E. Fowler, R. F. Hamman, J. M. Lachin, E. A. Walker and D. M. Nathan, Diabetes Prevention Program Research Group, Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin, N. Engl. J. Med.346 (2002) 393–403; https://doi.org/10.1056/NEJMoa01251210.1056/NEJMoa012512137092611832527Search in Google Scholar

11. S. Inoue, M. Egawa, S. Satoh, M. Saito, H. Suzuki, Y. Kumahara, M. Abe, A. Kumagai, Y. Goto and K. Shizume, Clinical and basic aspects of an anorexiant, mazindol, as an antiobesity agent in Japan, Am. J. Clin. Nutr.55 (1992) 199S–202S; https://doi.org/10.1093/ajcn/55.1.199s10.1093/ajcn/55.1.199sSearch in Google Scholar

12. T. Shiraishi, Mazindol effects on the salivary and gastric acid secretory mechanisms, Nihon Yakurigaku Zasshi (Folia Pharmacol.) 83 (1984) 159–172; https://doi.org/10.1254/fpj.83.15910.1254/fpj.83.159Search in Google Scholar

13. G. Slama, A. Selmi, M. Hautecouverture and G. Tchobroutsky, Double blind clinical trial of mazindol on weight loss blood glucose, plasma insulin and serum lipids in overweight diabetic patients, Diabet. Metab.4 (1978) 193–199.Search in Google Scholar

14. M. Usami, Y. Seino, S. Nishi, H. Nakahara, M. Ikeda, S. Matsukura and H. Imura, Effect of mazindol on insulin and glucagon secretion in ventromedial hypothalamic obese rats, Nihon Yakurigaku Zasshi (Folia Pharmacol.) 85 (1985) 297–303; https://doi.org/10.1254/fpj.85.29710.1254/fpj.85.297Search in Google Scholar

15. L. E. Cruz-Álvarez, A. Zúñiga-Romero, J. C. Huerta-Cruz, F. J. Flores-Murrieta, J. G. Reyes-García, C. I. Araiza-Saldaña and H. I. Rocha-González, Antiallodynic interaction and motor performance of the pregabalin/thioctic acid and pregabalin/α-tocopherol combinations in neonatal streptozotocin-induced diabetic rats, Drug Dev. Res. 79 (2018) 362–369; https://doi.org/10.1002/ddr.2147310.1002/ddr.21473Search in Google Scholar

16. S. Pellow, P. Chopin, S. E. File and M. Briley, Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat, J. Neurosci. Meth.14 (1985) 149–167; https://doi.org/10.1016/0165-0270(85)90031-710.1016/0165-0270(85)90031-7Search in Google Scholar

17. R. J. Tallarida, Drug Synergism and Dose-Effect Data Analysis, Chapman & Hall/CRC, New York 2000, pp. 1–264.10.1201/9781420036107Search in Google Scholar

18. R. J. Tallarida, The interaction index: a measure of drug synergism, Pain98 (2002) 163–168; https://doi.org/10.1016/S0304-3959(02)00041-610.1016/S0304-3959(02)00041-6Search in Google Scholar

19. T. Yoshida, T. Umekawa, Y. Wakabayashi, K. Yoshimoto, N. Sakane and M. Kondo, Anti-obesity and anti-diabetic effects of mazindol in yellow KK mice: its activating effect on brown adipose tissue thermogenesis, Clin. Exp. Pharmacol. Physiol.23 (1996) 476–482; https://doi.org/10.1111/j.1440-1681.1996.tb02764.x10.1111/j.1440-1681.1996.tb02764.xSearch in Google Scholar

20. R. C. Lucchetta, B. S. Riveros, R. Pontarolo, R. B. Radominski, M. F. Otuki, F. Fernandez-Llimos and C. J. Correr, Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients, Clinics (Sao Paulo) 72 (2017) 317–324; https://doi.org/10.6061/clinics/2017(05)1010.6061/clinics/2017(05)10Search in Google Scholar

21. J. Rouru, R. Huupponen, U. Pesonen and M. Koulu, Subchronic treatment with metformin produces anorectic effect and reduces hyperinsulinemia in genetically obese Zucker rats, Life Sci.50 (1992) 1813–1820; https://doi.org/10.1016/0024-3205(92)90066-X10.1016/0024-3205(92)90066-XSearch in Google Scholar

22. K. N. de Oliveira Santana, D. F. Lelis, K. L. Mendes, J. F. Lula, A. F. Paraíso, J. M. Andrade, J. D. Feltenberger, J. Cota, D. V. da Costa, A. M. de Paula, A. L. Guimarães and S. H. Santos, Metformin reduces lipogenesis markers in obese mice fed a low-carbohydrate and high-fat diet, Lipids51 (2016) 1375–1384; https://doi.org/10.1007/s11745-016-4209-y10.1007/s11745-016-4209-ySearch in Google Scholar

23. C. M. Ashwell and J. P. McMurtry, Hypoglycemia and reduced feed intake in broiler chickens treated with metformin, Poult. Sci.82 (2003) 106–110; https://doi.org/106-110.10.1093/ps/82.1.10610.1093/ps/82.1.106Search in Google Scholar

24. A. Saenz, I. Fernandez-Esteban, A. Mataix, M. Ausejo, M. Roque and D. Moher, Metformin mono-therapy for type 2 diabetes mellitus, Cochrane Database Syst. Rev.3 (2005) CD002966; https://doi.org/10.1002/14651858.CD002966.pub310.1002/14651858.CD002966.pub3Search in Google Scholar

25. S. K. Graff, F. M. Mario, P. Ziegelmann and P. M. Spritzer, Effects of orlistat vs. metformin on weight loss-related clinical variables in women with PCOS: systematic review and meta-analysis, Int. J. Clin. Pract.70 (2016) 450–461; https://doi.org/10.1111/ijcp.1278710.1111/ijcp.12787Search in Google Scholar

26. F. Hui, Y. Zhang, T. Ren, X. Li, M. Zhao and Q. Zhao, Role of metformin in overweight and obese people without diabetes: a systematic review and network meta-analysis, Eur. J. Clin. Pharmacol.75 (2019) 437–450; https://doi.org/10.1007/s00228-018-2593-310.1007/s00228-018-2593-3Search in Google Scholar

27. L. C. Iorio, E. A. Ryan and J. H. Gogerty, Combinations of selected CNS depressants with d-amphetamine or mazindol on food intake and motor activity of rats, Eur. J. Pharmacol.36 (1976) 89–94; https://doi.org/10.1016/0014-2999(76)90260-010.1016/0014-2999(76)90260-0Search in Google Scholar

28. Z. L. Kruk and M. R. Zarrindast, Mazindol anorexia is mediated by activation of dopaminergic mechanisms, Br. J. Pharmacol.58 (1976) 367–372; https://doi.org/10.1111/j.1476-5381.1976.tb07713.x10.1111/j.1476-5381.1976.tb07713.xSearch in Google Scholar

29. N. Shimizu, S. Take, T. Hori and Y. Oomura, Hypothalamic microdialysis of mazindol causes anorexia with increase in synaptic serotonin in rats, Physiol. Behav.49 (1991) 131–134; https://doi.org/10.1016/0031-9384(91)90243-H10.1016/0031-9384(91)90243-HSearch in Google Scholar

30. R. G. Engstrom, L. A. Kelly and J. H. Gogerty, The effects of 5-hydroxy-5(4’-chlorophenyl)-2,3-di-hydro-5H-imidazo(2,1-a)isoindole(mazindol, SaH 42-548) on the metabolism of brain norepinephrine, Arch. Int. Pharmacodyn. Ther.214 (1975) 308–321.Search in Google Scholar

31. S. K. Sikdar, Y. Oomura and A. Inokuchi, Effects of mazindol on rat lateral hypothalamic neurons, Brain Res. Bull.15 (1985) 33–38; https://doi.org/10.1016/0361-9230(85)90058-910.1016/0361-9230(85)90058-9Search in Google Scholar

32. S. Inoue, M. Tsuchiya and Y. Takamura, Effects of mazindol on food intake in ventromedial hypothalamic lesioned rats and glucose absorption in rats, Int. J. Obes.11 (1987) 63–69.Search in Google Scholar

33. M. J. Kirby and P. Turner, Do „anorectic” drugs produce weight loss by appetite suppression? Lancet1 (1976) 566–567; https://doi.org/10.1016/S0140-6736(76)90360-310.1016/S0140-6736(76)90360-3Search in Google Scholar

34. D. Stevanovic, K. Janjetovic, M. Misirkic, L. Vucicevic, M. Sumarac-Dumanovic, D. Micic, V. Starcevic and V. Trajkovic, Intracerebroventricular administration of metformin inhibits ghrelin-induced hypothalamic AMP-kinase signalling and food intake, Neuroendocrinology96 (2012) 24–31; https://doi.org/10.1159/00033396310.1159/000333963Search in Google Scholar

35. W. S. Lv, J. P. Wen, L. Li, R. X. Sun, J. Wang, Y. X. Xian, C. X. Cao, Y. L. Wang and Y. Y. Gao, The effect of metformin on food intake and its potential role in hypothalamic regulation in obese diabetic rats, Brain Res.1444 (2012) 11–19; https://doi.org/10.1016/j.brainres.2012.01.02810.1016/j.brainres.2012.01.028Search in Google Scholar

36. R. J. Rodgers and A. Dalvi, Anxiety, defence and the elevated plus-maze, Neurosci. Biobehav. Rev.21 (1997) 801–810; https://doi.org/10.1016/S0149-7634(96)00058-910.1016/S0149-7634(96)00058-9Search in Google Scholar

37. R. Mattei and E. A. Carlini, Mazindol: anorectic and behavioral effects in female rats, Arch. Int. Pharmacodyn. Ther.330 (1995) 279–287.Search in Google Scholar

38. G. Gariepy, D. Nitka and N. Schmitz, The association between obesity and anxiety disorders in the population: a systematic review and meta-analysis, Int. J. Obes. (London) 34 (2010) 407–419; https://doi.org/10.1038/ijo.2009.25210.1038/ijo.2009.252Search in Google Scholar

39. D. E. Smith, M. D. Marcus and K. L. Eldredge, Binge eating syndromes: A review of assessment and treatment with an emphasis on clinical application, Behav. Ther.25 (1994) 635–665; https://doi.org/10.1016/S0005-7894(05)80202-310.1016/S0005-7894(05)80202-3Search in Google Scholar

40. S. R. Salpeter, N. S. Buckley, J. A. Kahn and E. E. Salpeter, Meta-analysis: metformin treatment in persons at risk for diabetes mellitus, Am. J. Med.121 (2008) 149–157; https://doi.org/10.1016/j.amjmed.2007.09.01610.1016/j.amjmed.2007.09.01618261504Search in Google Scholar

Artículos recomendados de Trend MD

Planifique su conferencia remota con Sciendo